Aragen Bioscience, Inc., today announced it is a subcontractor on a National Institute of Allergy and Infectious Diseases (NIAID) contract for the preclinical development of monoclonal antibodies for the prevention and treatment of infectious diseases.
Aragen Bioscience was awarded three subcontracts to generate and characterize stable cell lines expressing antibodies against polio virus, pandemic influenza virus and Candida albicans, and to develop cell culture and purification processes to produce the antibodies for preclinical studies.
"We are pleased to be working with Aragen Bioscience on these important projects," said Jon Mirsalis, Ph.D., D.A.B.T., managing director of SRI International's Biosciences Division and principal investigator for the contract from NIAID, part of the National Institutes of Health. "Working together, we will advance promising therapeutics to the clinic."
"These novel antibodies represent the next generation in infectious disease treatment," said Rick Srigley, president and CEO of Aragen Bioscience. "We look forward to supporting this important work in developing these new therapies."
When CDK12/13 stalls, healthy prostate cells take a malignant turn